home / stock / pirs / pirs quote
Last: | $0.1832 |
---|---|
Change Percent: | 3.98% |
Open: | $0.186 |
Close: | $0.1832 |
High: | $0.1925 |
Low: | $0.1831 |
Volume: | 398,503 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.1832 | $0.186 | $0.1832 | $0.1925 | $0.1831 | 398,503 | 03-28-2024 |
$0.1937 | $0.19 | $0.1937 | $0.1955 | $0.1817 | 1,238,321 | 03-27-2024 |
$0.188 | $0.1825 | $0.188 | $0.198 | $0.1825 | 358,787 | 03-26-2024 |
$0.1817 | $0.194 | $0.1817 | $0.2 | $0.179 | 2,968,260 | 03-25-2024 |
$0.2 | $0.2 | $0.2 | $0.22 | $0.1961 | 735,308 | 03-22-2024 |
$0.1999 | $0.209 | $0.1999 | $0.21 | $0.19 | 650,589 | 03-21-2024 |
$0.21 | $0.24 | $0.21 | $0.2401 | $0.2051 | 763,334 | 03-20-2024 |
$0.2155 | $0.2123 | $0.2155 | $0.245 | $0.201 | 2,482,456 | 03-19-2024 |
$0.21 | $0.1785 | $0.21 | $0.279 | $0.1752 | 9,543,639 | 03-18-2024 |
$0.169 | $0.167 | $0.169 | $0.1772 | $0.1626 | 346,346 | 03-15-2024 |
$0.171 | $0.1795 | $0.171 | $0.1795 | $0.17 | 350,001 | 03-14-2024 |
$0.1743 | $0.166 | $0.1743 | $0.1843 | $0.165 | 292,243 | 03-13-2024 |
$0.171 | $0.165 | $0.171 | $0.18 | $0.155 | 614,491 | 03-12-2024 |
$0.17 | $0.186 | $0.17 | $0.186 | $0.167 | 229,486 | 03-11-2024 |
$0.18 | $0.1788 | $0.18 | $0.1865 | $0.1693 | 585,060 | 03-08-2024 |
$0.1779 | $0.168 | $0.1779 | $0.18 | $0.168 | 330,445 | 03-07-2024 |
$0.1691 | $0.175 | $0.1691 | $0.18 | $0.168 | 484,403 | 03-06-2024 |
$0.172 | $0.171 | $0.172 | $0.1849 | $0.1709 | 1,128,483 | 03-05-2024 |
$0.1699 | $0.1718 | $0.1699 | $0.173 | $0.1652 | 290,046 | 03-04-2024 |
$0.173 | $0.1689 | $0.173 | $0.173 | $0.1643 | 246,955 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin ® (antibody-Anticalin fusion) protein immuno-oncolo...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...